KMT2A and acute lymphoblastic leukemia: This approach allowed us to investigate the potential relationship between tissue-specific leukemia burden and the presence of ctDNA, providing potential insights into the utility of ctDNA as a biomarker for monitoring treatment response and detecting occult disease in infant MLL-r ALL.